View Clinical Trial (Medical Research Study)

Eczema Prevention Study - NCT00806221-97239(Clinical Trial 258642)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Portland
State:  
OR
Zip Code: 97239
Conditions: Atopic Dermatitis
Purpose: The purpose of this study is to determine whether early use of a bland emollient in newborns, prior to the clinical signs of skin disease, will delay the onset or prevent the development of atopic dermatitis.
Study summary: All neonates will be treated with Cetaphil cream starting within 1 week of birth. All neonates enrolled will have an increased risk of developing atopic dermatitis because they have a family history of either asthma, hay fever, or atopic dermatitis. These neonates will then be followed for 2 years for the signs and symptoms of atopic dermatitis.
Criteria: Inclusion Criteria: - at least one parent diagnosed with Atopic Dermatitis - one parent or sibling with hayfever or asthma Exclusion Criteria: - newborns with dermatitis at birth - newborns born greater than four weeks prematurely - newborns with medical problems necessitating prolonged hospitalization - newborns diagnosed with any immune deficiency syndrome
Study is available at: Oregon Health & Science University, Department of Dermatology
Portland, OR 97239
United States

Primary Contact:
Maureen Keene
Phone: 503-228-7350

Secondary Contact:
Maureen Keene
Phone: 503-228-7350
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 22, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.